CTLA4 and neoplasm: While systemic anti-CTLA-4 therapy has the potential to disrupt tumor-associated immunosuppression through multiple pathways and at multiple sites, targeted delivery to TDLN has been shown in animal models to promote proportionally greater T-cell activation and systemic tumor control [11].